Liafensine

Drug Profile

Liafensine

Alternative Names: BMS-820836

Latest Information Update: 02 Sep 2015

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antidepressants; Isoquinolines; Naphthalenes; Pyridazines; Small molecules; Tetrahydroisoquinolines
  • Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Major depressive disorder

Most Recent Events

  • 01 Oct 2013 Bristol-Myers Squibb discontinues a phase II trial in Major depressive disorder (treatment resistant) (NCT01361555)
  • 31 May 2013 Bristol-Myers Squibb completes a phase II trial in Argentina, Australia, Austria, Canada, France, India, Italy, Puerto Rico, South Africa, Spain, United Kingdom and USA (NCT01369095)
  • 01 Feb 2013 Phase-II clinical trials in Major depressive disorder (treatment-experienced) in Argentina (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top